Clinical Trial News and Research

RSS

Study may allow patients with multiple breast lesions to consider breast-conserving therapy as treatment option

Patients with multiple tumors in the same breast who underwent a lumpectomy followed by radiation therapy had local recurrence rates comparable to those historically observed in patients with a single tumor, according to results from the ACOSOG Z11102 (Alliance) prospective phase II clinical trial, which were presented at the San Antonio Breast Cancer Symposium, held December 6-10, 2022.

9 Dec 2022

Scientists trace how livestock systems act as a reservoir for antimicrobial-resistant bacteria

Scientists from the International Livestock Research Institute (ILRI), the University of Liverpool, the University of Edinburgh and elsewhere have traced how livestock systems act as a reservoir for antimicrobial-resistant (AMR) bacteria and AMR genetic determinants that may infect or colonize people.

9 Dec 2022

Addition of capivasertib to fulvestrant doubles progression-free survival in HR-positive breast cancer patients

In patients with hormone receptor (HR)-positive, HER2-negative tumors resistant to aromatase inhibitors, addition of the investigational AKT inhibitor capivasertib to fulvestrant (Faslodex) doubled the median progression-free survival compared with placebo plus fulvestrant in the phase III CAPItello-291 clinical trial, according to results presented at the San Antonio Breast Cancer Symposium, held December 6-10, 2022.

9 Dec 2022

Estrogen replacement therapy may be a tool to mitigate delirium

Delirium is common among women with urinary tract infections (UTIs) - especially those who have experienced menopause.

8 Dec 2022

Therapeutic activation of p53 could offer new treatment option for salivary gland cancer

Researchers at the University of Michigan Rogel Cancer Center and School of Dentistry found that certain drugs can change the fundamental makeup of cancer stem cells in mouse models of mucoepidermoid carcinoma – a lethal form of salivary gland cancer that currently has no treatment options.

8 Dec 2022

Multi-stage HIV vaccine regimen shows promising results in Phase 1 clinical trial

The George Washington University Vaccine Research Unit in partnership with Scripps Research, IAVI, Fred Hutchinson Cancer Center (FHCC) and the National Institutes of Health, National Institute of Allergy and Infectious Diseases Vaccine Research Center published the results of their Phase 1 Clinical Trial in Science.

8 Dec 2022

For patients with sickle cell disease, fertility care is about reproductive justice

Teonna Woolford has always wanted six kids. Why six? "I don't know where that number came from. I just felt like four wasn't enough," said Woolford, a Baltimore resident. "Six is a good number."

8 Dec 2022

Updated results on a new approach to treating advanced ER-positive/HER2-negative breast cancer

A UCLA Jonsson Comprehensive Cancer Center researcher and collaborators in a multicenter study will present updated results and plans for further research on a new approach to treating advanced ER-positive/HER2-negative breast cancer.

7 Dec 2022

UK's Newton Fund supported Mexican scientist to develop vaccines against Chikungunya, Zika and Dengue

Dr Arturo Reyes Sandoval is the Director of the National Polytechnic Institute, one of the largest and most prestigious universities in Mexico.

7 Dec 2022

T-DXd leads to longer overall survival in HER2-positive metastatic breast cancer patients than T-DM1

Second-line treatment with trastuzumab deruxtecan (T-DXd) led to significantly longer overall survival compared with trastuzumab emtansine (T-DM1) in patients with HER2-positive metastatic breast cancer, according to updated results from the DESTINY-Breast03 phase III clinical trial presented at the San Antonio Breast Cancer Symposium, held December 6-10, 2022.

7 Dec 2022

T-DXd shows high efficacy in HER2-positive breast cancer patients previously treated with T-DM1

Compared with capecitabine-based regimens, trastuzumab deruxtecan (T-DXd) led to higher response rates and longer survival in the third-line setting for patients with HER2-positive metastatic breast cancer previously treated with trastuzumab emtansine (T-DM1), according to results from the phase III DESTINY-Breast02 trial presented at the San Antonio Breast Cancer Symposium, held December 6-10, 2022.

7 Dec 2022

Researchers share results of MVA-BN-respiratory syncytial virus vaccine human challenge trial

Researchers reported the immunogenicity, efficacy, and safety of the MVA-BN (modified vaccinia Ankara-Bavarian Nordic)-RSV (respiratory syncytial virus) vaccine against RSV-A (RSV subtype A) Memphis 37b strain in a human challenge trial.

7 Dec 2022

Study allows people with type 2 diabetes to choose their own medication

A large-scale new study offers a new approach to treating type 2 diabetes - that puts patients in charge of their own medication. The Trimaster study is the first to allow people with type 2 diabetes to choose their own medication, after trying three different drugs in succession.

7 Dec 2022

Study reports overall response of HER2-low breast cancer patients to neoadjuvant T-DXd treatment

Patients with localized, hormone receptor-positive, HER2-low breast cancer treated with trastuzumab deruxtecan (T-DXd, Enhertu) in the neoadjuvant setting had an overall response rate of 75 percent in the absence of anastrozole and 63 percent in combination with anastrozole, according to results from the phase II TRIO-US B-12 TALENT trial presented at the San Antonio Breast Cancer Symposium, held December 6-10, 2022.

7 Dec 2022

Exploring immunogenicity, boosting efficacy and safety of modified vaccinia Ankara-Bavarian Nordic vaccine

Researchers evaluated the immunogenicity, boosting efficacy, and safety of single-dose and two-dose MVA-BN (modified vaccinia Ankara-Bavarian Nordic) vaccinations in comparison to replicating smallpox vaccines.

7 Dec 2022

Paper-based synthetic biosensor could help easily detect toxin putrescine in beef

The supply chain that brings meat to market worldwide is highly complex and usually very efficient. But when disruptions in one part of the world can result in transportation delays an ocean and a continent away, meat spoilage becomes a very real risk to food producers, vendors and consumers.

6 Dec 2022

Discovery of three new brain tumor subtypes could help to identify novel, effective therapies

Research lead by RCSI University of Medicine and Health Sciences has discovered three new subtypes of brain tumor which could help to identify new and effective therapies.

6 Dec 2022

Largest machine learning effort securely aggregates data from brain scans of glioblastoma patients

Researchers at Penn Medicine and Intel Corporation led the largest-to-date global machine learning effort to securely aggregate knowledge from brain scans of 6,314 glioblastoma (GBM) patients at 71 sites around the globe and develop a model that can enhance identification and prediction of boundaries in three tumor sub-compartments, without compromising patient privacy.

6 Dec 2022

The critical role of flow cytometry in CAR+ T-Cell trials

In this interview, Ryan Muise talks to AZoNetwork about the added value of using flow cytometry in CAR T-Cell clinical trials.

From Cerba Research 6 Dec 2022

Is remdesivir treatment associated with reduced risk of inpatient mortality among US patients hospitalized with COVID-19?

Researchers assessed the effect of remdesivir on inpatient COVID-19-associated mortality among individuals hospitalized with SARS-CoV-2 infections in an enormous dataset of US residents beyond clinical trial settings.

6 Dec 2022

Clinical Trial News and Research

Study may allow patients with multiple breast lesions to consider breast-conserving therapy as treatment option

Scientists trace how livestock systems act as a reservoir for antimicrobial-resistant bacteria

Addition of capivasertib to fulvestrant doubles progression-free survival in HR-positive breast cancer patients

Estrogen replacement therapy may be a tool to mitigate delirium

Therapeutic activation of p53 could offer new treatment option for salivary gland cancer

Multi-stage HIV vaccine regimen shows promising results in Phase 1 clinical trial

For patients with sickle cell disease, fertility care is about reproductive justice

Updated results on a new approach to treating advanced ER-positive/HER2-negative breast cancer

UK's Newton Fund supported Mexican scientist to develop vaccines against Chikungunya, Zika and Dengue

T-DXd leads to longer overall survival in HER2-positive metastatic breast cancer patients than T-DM1

T-DXd shows high efficacy in HER2-positive breast cancer patients previously treated with T-DM1

Researchers share results of MVA-BN-respiratory syncytial virus vaccine human challenge trial

Study allows people with type 2 diabetes to choose their own medication

Study reports overall response of HER2-low breast cancer patients to neoadjuvant T-DXd treatment

Exploring immunogenicity, boosting efficacy and safety of modified vaccinia Ankara-Bavarian Nordic vaccine

Paper-based synthetic biosensor could help easily detect toxin putrescine in beef

Discovery of three new brain tumor subtypes could help to identify novel, effective therapies

Largest machine learning effort securely aggregates data from brain scans of glioblastoma patients

The critical role of flow cytometry in CAR+ T-Cell trials

Is remdesivir treatment associated with reduced risk of inpatient mortality among US patients hospitalized with COVID-19?

Event guide: 15th World Clinical Biomarkers & CDx Europe eBook

Latest eBooks

Industry Focus eBook - Life Science Microscopy (2nd Edition)

Event guide: 2nd World RNA-Based Therapeutics & Vaccines Summit Korea

New horizons in drug discovery: High-throughput & target-to-therapy advances

A practical guide to lipid nanoparticle formulation and resizing

The impact of vibration on microscopy

How Omics Technologies Are Transforming Biological Research and Drug Discovery

How microplastics and bacteria interact to drive antibiotic resistance